Genomics Services
 
 
ALK (Anaplastic Lymphoma Kinase)
Recommended for Non Small Cell Lung Cancer and Solid Malignancies

The EML4-ALK fusion gene is responsible for approximately 3-5% of Non Small Cell Lung Cancer. The vast majority of cases are adenocarcinomas. Rearrangements of the gene encoding ALK have been linked to abnormal cell proliferation and NSCLC. The most common ALK rearrangement in NSCLC is EML4-ALK, which arises from fusion between the EML4 gene and the ALK gene on chromosome 2p23. Patients with ALK rearrangements do not respond to the EGFR-specific TKI therapy. ALK gene rearrangements have implications in both Hematological and Solid Malignancies.

Sample Type

FFPE Tissue: Formalin Fixed Parafin Embedded (FFPE) tissue block with atleast 3-4 sections of tumor tissue. Tissue section should contain >70% tumor content verified by pathologist and should be sent along with 5 H&E stained and 5 unstained slides of tumor tissue.

Fresh Tissue: Fresh tissue in tms RNS stabilizer (XGtms-100) provided by Xcelris Labs in sterile leak proof container at -20°C (in Dry Ice)
 
Brochure           inquiry
 
 
EGFR (Epidermal Growth Factor Receptor)   |   ALK (Anaplastic lymphoma kinase)
BRAF (B-Raf proto-oncogene, serine/threonine kinase)   |   BRCA1 and BRCA2   |   CHECK2 (Check Point Homolog)
KRAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)   |   Tyrosine Kinase Sensitivity for KIT & PDGFRA
HER2 (Human Epidermal Growth factor Receptor 2) or ERBB2   |   TP53 (Tumor Protein p53)   |   BCR-ABL
Tamoxifen   |   NRAS Mutation   |   Tyrosine Kinase Sensitivity for Abl1 Mutations
HRAS Mutation (Harvey rat sarcoma viral Oncogene Homolog)   |   DPYD Mutation (for 5FU Sensitivity)
MAPK1 Mutation Analysis
 
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom
 
Click Here to Zoom